Goldman Sachs’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Goldman Sachs’s Portfolio SNNA Stock Details SNNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-52,553	Closed	-$11K	–	5531
2019 Q3	$11K	Buy	52,553 +6,118	+13%	+$4.14K	﹤0.01%	5128
2019 Q2	$40K	Sell	46,435 -374	-0.8%	-$585	﹤0.01%	5032
2019 Q1	$109K	Buy	46,809 +30,109	+180%	+$81.6K	﹤0.01%	4918
2018 Q4	$39K	Sell	16,700 -7,335	-31%	-$64.7K	﹤0.01%	5113
2018 Q3	$356K	Buy	24,035 +10,102	+73%	+$161K	﹤0.01%	4614
2018 Q2	$212K	Buy	13,933 +1,932	+16%	+$32.8K	﹤0.01%	4972
2018 Q1	$225K	Buy	12,001 +1,259	+12%	+$22K	﹤0.01%	4938
2017 Q4	$195K	Buy	+10,742	New	+$227K	﹤0.01%	5441

Other funds holding SNNA

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Private Ocean San Rafael, California $1.13B AUM 11.01% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs's SNNA Position: Q4 2019 in Review

Goldman Sachs sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q4 2019, closing a stake of 52,553 shares — an estimated $11K sold.

Goldman Sachs first reported a position in SNNA in Q4 2017 and held it in 8 quarters. The position peaked at $356K in Q3 2018. 4 funds tracked by Wall St. Rank hold SNNA as of Q4 2019.

Goldman Sachs reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
Goldman Sachs sold 52,553 Sienna Biopharmaceuticals, Inc. shares in Q4 2019, an estimated $11K.
Goldman Sachs first reported a position in Sienna Biopharmaceuticals, Inc. in Q4 2017 and held it in 8 quarters.
Goldman Sachs's Sienna Biopharmaceuticals, Inc. position peaked at $356K in Q3 2018.
4 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q4 2019.

Based on Goldman Sachs's 13F filing for Q4 2019, filed 14 Feb 2020.